{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:07:26Z","timestamp":1787497646104,"version":"build-2736575974"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>In clinical studies GS-US-380-1489 (study 1489) and GS-US-380-1490 (study 1490), bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF), dolutegravir-abacavir-lamivudine (DTG-ABC-3TC), and dolutegravir plus emtricitabine-tenofovir alafenamide (DTG+F-TAF) treatment achieved high rates of virologic suppression in HIV-1 treatment-naive participants through week 48. Preexisting primary drug resistance was present at levels of 1.3% integrase strand transfer inhibitor resistance (INSTI-R), 2.7% nucleoside reverse transcriptase inhibitor resistance (NRTI-R), 14.1% nonnucleoside reverse transcriptase inhibitor resistance (NNRTI-R), and 3.5% protease inhibitor resistance (PI-R) in the 1,274 participants from these studies.<\/jats:p>","DOI":"10.1128\/aac.02533-18","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T08:58:20Z","timestamp":1551171500000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":46,"title":["Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks"],"prefix":"10.1128","volume":"63","author":[{"given":"Rima K.","family":"Acosta","sequence":"first","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Willkom","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Martin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Chang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Wei","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Garner","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lutz","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Majeed","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi","family":"SenGupta","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hal","family":"Martin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Quirk","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten L.","family":"White","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2018","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. 2018. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services, Washington, DC."},{"key":"e_1_3_2_3_2","volume-title":"Guidelines, version 9.0. (English)","author":"European AIDS Clinical Society (EACS)","year":"2017","unstructured":"European AIDS Clinical Society (EACS). 2017. Guidelines, version 9.0. (English). European AIDS Clinical Society, London, United Kingdom."},{"key":"e_1_3_2_4_2","volume-title":"BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use, package insert","author":"Gilead Sciences, Inc","year":"2018","unstructured":"Gilead Sciences, Inc. 2018. BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use, package insert. Gilead Sciences, Inc., Foster City, CA."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-16"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"e_1_3_2_8_2","first-page":"67","article-title":"HIV-1 drug resistance mutations: an updated framework for the second decade of HAART","volume":"10","author":"Shafer RW","year":"2008","unstructured":"Shafer RW, Schapiro JM. 2008. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 10:67\u201384.","journal-title":"AIDS Rev"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004724"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000494"},{"key":"e_1_3_2_11_2","volume-title":"HIV drug resistance report 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. 2017. HIV drug resistance report 2017. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01535-07"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv333"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv243"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit697"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg100"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006687"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2010.0123"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61853-4"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60084-2"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30095-4"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1083"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001494"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw071"},{"key":"e_1_3_2_27_2","unstructured":"Blanco JL Oldenbuettel C Thomas R Mallolas J Wolf E Brenner B Spinner CD Wainberg MA Martinez E. 2017. Pathways of resistance in subjects failing dolutegravir monotherapy abstr 42. Abstr Conf Retrovir Opportunistic Infect Seattle WA 13 to 16 February 2017."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30152-2"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"e_1_3_2_31_2","unstructured":"Kityo C Hagins D Koenig E Avihingsanon A Chetchotisakd P Supparatpinyo K Gankina N Pokrovsky V Voronin E Stephens JL DeJesus E Wang H Quirk E Martin H Makadzange T. 2018. Switching to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in women poster 500. Abstr Conf Retroviruses Opportunistic Infect Boston MA 4 to 7 March 2018."},{"key":"e_1_3_2_32_2","unstructured":"Andreatta K Chang S Martin R Willkom M White KL. 2018. Integrase inhibitor resistance selections initiated with drug resistant HIV-1 poster 546. Abstr Conf Retroviruses Opportunistic Infect Boston MA 4 to 7 March 2018."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0440-3"},{"key":"e_1_3_2_34_2","unstructured":"International Antiviral Society\u2014USA. 2017. Drug resistance mutations in HIV-1. https:\/\/www.iasusa.org\/content\/drug-resistance-mutations-in-HIV."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02533-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02533-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:32:39Z","timestamp":1645461159000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02533-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1128\/AAC.02533-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.02533-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"2018-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02533-18"}}